Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: Acute and repeated treatment
- 1 January 1992
- Vol. 10 (1), 25-33
- https://doi.org/10.1002/syn.890100105
Abstract
Sertindole (Lundbeck code No. Lu 23‐174) (1‐[2‐[4‐[5‐chloro‐1‐(4‐fluorophenyl)‐1H‐indol‐3‐yl]‐1‐piperidinyl]ethyl]‐2‐ imidazolidinone) is a new potential neuroleptic compound. After 3 weeks of treatment sertindole shows an extreme selectivity to inhibit the number of spontaneously active dopaminergic (DA) neurones in ventral tegmental area (VTA) while leaving the number of active DA neurones in substantia nigra pars compacta (SNC) unaffected. Acute injection of apomorphine or baclofen reverse the inhibition of activity seen after repeated treatment with sertindole. This suggests that sertindole induces a depolarization inactivation of the DA neurones. The depolarization inactivation is reversible since normal activity of DA neurones is found in both SNC and VTA after two weeks withdrawal from repeated treatment with a low dose with sertindole. One or two weeks administration of a high dose of sertindole induced only minor effects on the DA neurones in VTA; i.e., in order to obtain the depolarization inactivation sertindole requires 3 weeks of treatment as has also been reported for other neuroleptics. Three weeks of treatment with clozapine induces a selective inhibition of the active DA neurones in VTA but at much higher doses than seen with sertindole, while haloperidol induces a non‐selective decrease of spontaneously active DA neurones in both areas. In acute electrophysiological experiments intraveneous (i.v.) administration of sertindole—in contrast to both clozapine and haloperidol—neither reverse d‐amphetamine‐ nor apomorphine‐induced inhibition of the firing frequencies of DA neurones in SNC or in VTA. In addition, sertindole does not—even in high doses—increase the firing frequency of DA neurones in SNC or VTA. In conclusion the study indicates that sertindole is a potential antipsychotic compound which should induce fewer extrapyramidal side‐effects than seen after classical neuroleptics.Keywords
This publication has 14 references indexed in Scilit:
- Neurochemical and in vivo pharmacological profile of sertindole, a limbic‐selective neuroleptic compoundDrug Development Research, 1991
- Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the ratEuropean Journal of Pharmacology, 1990
- The 5‐HT2 antagonist ritanserin blocks the effect of pre‐frontal cortex inactivation on rat A10 dopamine neurons in vivoActa Physiologica Scandinavica, 1989
- Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibitionPsychopharmacology, 1989
- Dopamine-containing neurons in the mammalian central nervous system: Electrophysiology and pharmacologyNeuroscience & Biobehavioral Reviews, 1988
- Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurones in ratsLife Sciences, 1988
- Chronic haloperidol decreases dopamine release in striatum and nucleus accumbens in vivo: Depolarization block as a possible mechanism of actionBrain Research Bulletin, 1987
- Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine NeuronsScience, 1983
- Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activityLife Sciences, 1978
- d -Amphetamine-Induced Inhibition of Central Dopaminergic Neurons: Mediation by a Striato-Nigral Feedback PathwayScience, 1976